文献速递主动脉疾病内脏/肾动脉与血管畸形

Viabahn球囊扩张式内支架作为开窗与分支腔内主动脉修复桥接支架的中期结局

Mid-Term Outcomes of the Viabahn Balloon-Expandable Endoprosthesis as Bridging Stent Graft for Fenestrated and Branched Endovascular Aortic Repair.
PubMed 文献 · J Endovasc Ther · 2024-11-22

本研究回顾性分析2019年1月至2023年5月连续87例接受开窗/分支腔内主动脉修复(F/B-EVAR)并使用至少1枚Viabahn VBX作为桥接支架的患者,共植入273枚VBX于263个靶血管。VBX植入技术成功率97.5%(273/280次尝试),12个月免于VBX相关不良事件在开窗靶血管为96.6%、分支靶血管为93.6%,中位随访14个月总生存率86.7%。作者认为VBX作为桥接支架表现优异,但需等待长期随访数据。

要点

  • VBX桥接支架植入技术成功率为97.5%(273/280次尝试)。
  • 12个月免于VBX相关不良事件:开窗靶血管96.6%,分支靶血管93.6%。
  • 12个月免于靶血管不稳定:开窗98.1%,分支97.6%。

核心结论

  • VBX支架作为F/B-EVAR中的桥接支架表现优异,开窗与分支靶血管均有高的技术植入成功率和高的中期免于支架相关不良事件及靶血管不稳定率。
  • 作者指出需等待VBX支架性能的长期随访数据。

研究设计与样本

  • 回顾性分析2019年1月至2023年5月连续接受F/B-EVAR治疗胸腹或复杂腹主动脉瘤且使用至少1枚VBX作为桥接支架的患者。
  • 共纳入87例患者(74.7%男性;平均年龄73.6±7.0岁),植入38枚FEVAR、46枚BEVAR和3枚F/B-EVAR(联合设计)支架,共273枚VBX植入于263个靶血管。
  • 主要结局为VBX支架植入的技术成功;次要终点为VBX相关不良事件、靶血管不稳定、内漏和总生存。

主要发现

  • VBX植入技术成功率为97.5%(273/280次尝试成功)。
  • VBX相关次要终点评估了269枚VBX于259个靶血管;靶血管设计包括107个开窗(41.3%)、82个外分支(31.7%)和70个内分支(27.0%)。
  • 术后12个月免于VBX相关不良事件:开窗靶血管96.6%(95%CI:92.9%-100%),分支靶血管93.6%(95%CI:89.4%-98.0%)。
  • 术后12个月免于靶血管不稳定:开窗98.1%(95%CI:94.4%-100%),分支97.6%(95%CI:94.9%-100%)。
  • 随访期间共检出9例(3.5%)VBX相关内漏;中位随访14个月,全部治疗患者总生存率为86.7%(95%CI:79.1%-94.9%)。

临床怎么用

  • 作者认为VBX支架作为F/B-EVAR中的桥接支架表现优异,具有高技术植入成功率和高的中期免于支架相关不良事件及靶血管不稳定率。
  • 作者指出需等待VBX支架性能的长期随访数据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bridging stent grafts (BSG) implanted during fenestrated and branched endovascular aortic repair (F/B-EVAR) are crucial for the successful exclusion of thoracoabdominal and complex abdominal aortic aneurysms (AAA). The aim of this study was to analyze the outcomes of the Gore Viabahn VBX stent graft as BSG for renal and visceral target vessels during F/B-EVAR. MATERIALS AND METHODS: All consecutive patients undergoing F/B-EVAR for thoracoabdominal or complex AAAs from January 2019 to May 2023 who were treated with at least 1 VBX stent graft as BSG were included. Procedural, radiological, and follow-up data of the included patients were retrospectively reviewed. Primary outcome of the study was technical success of VBX stent graft implantation. Secondary endpoints were VBX-related adverse events, target vessel instability, endoleaks, and overall survival. RESULTS: A total of 273 VBX stent grafts were implanted in 263 target vessels in 38 FEVAR, 46 BEVAR, and 3 F/B-EVAR (combined design) stent grafts in 87 patients (74.7% male; mean age, 73.6 ± 7.0 years). Technical success of VBX stent graft implantation was 97.5% with 273 successful implantations in 280 attempts. The VBX-related secondary endpoints were evaluated for 269 VBX stent grafts in 259 target vessels. Target vessel designs included 107 fenestrations (41.3%), 82 outer-branches (31.7%), and 70 inner-branches (27.0%). Freedom from VBX-related adverse events at 12 months postoperatively was 96.6% (95% CI: 92.9%-100%) for target vessels with a fenestration and 93.6% (95% CI: 89.4%-98.0%) for target vessels with a branch. Freedom from target vessel instability at 12 months postoperatively for fenestrations and branches was 98.1% (95% CI: 94.4%-100%) and 97.6% (95% CI: 94.9%-100%) respectively. A total of 9 (3.5%) VBX-related endoleaks were detected during follow-up. Overall survival of all treated patients was 86.7% (95% CI: 79.1%-94.9%) at a median follow-up of 14 months. CONCLUSION: The VBX stent graft shows an excellent performance as a BSG in F/B-EVAR. The VBX stent graft has a high technical implantation success and shows a high mid-term freedom from stent graft-related adverse events and target vessel instability for both target vessels with a fenestration and a branch. Long-term follow-up data of the performance of the VBX stent graft are to be awaited.Clinical ImpactThis study evaluated the outcomes of the Gore Viabahn VBX stent graft as a bridging stent graft (BSG) for renal and visceral target vessels. It is important to evaluate the performance of such recently introduced stent grafts as these are essentially used in procedures outside of the Instructions for Use. This comprehensive analysis of the VBX stent graft as a BSG adds to the evidence of the performance of this stent graft as a BSG.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Kappe KO, van Knippenberg SEM, Tran BL, et al. Mid-Term Outcomes of the Viabahn Balloon-Expandable Endoprosthesis as Bridging Stent Graft for Fenestrated and Branched Endovascular Aortic Repair. J Endovasc Ther. 2024. PMID: 39575702. doi:10.1177/15266028241300005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。